Increasing evidence that hepatitis B virus X gene protein and p53 protein may interact in the pathogenesis of hepatocellular carcinoma

Hepatology

Volumn 25, Issue 4, 1997, Pages 1037-1038

  Wang, X W ^a   Gibson, M K ^a   Vermeulen, W ^a   Yeh, H ^a   Forrester, K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; PROTEIN P53;

APOPTOSIS; ETIOLOGY; GENE MUTATION; GENE REPRESSION; HEPATITIS B VIRUS; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; NONHUMAN; NOTE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; VIRUS GENE;

CARCINOMA, HEPATOCELLULAR; COCARCINOGENESIS; GENES, VIRAL; HEPATITIS B VIRUS; HUMANS; LIVER NEOPLASMS; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 20644433331     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510250442     Document Type: Note

References (16)

1. Henkler F, Koshy R. Hepatitis B virus transcriptional activators: mechanisms and possible role in oncogenesis. J Vir Hepatit 1996;3:109-121.
2. Cross JC, Wen P, Rutter WJ. Transactivation by hepatitis B virus X protein is promiscuous and dependent on mitogen-activated cellular serine/threonine kinases. Proc Natl Acad Sci U S A 1993;90:8078-8082.
3. Kew MC. Hepatitis B and C viruses and hepatocellular carcinoma. Clin Lab Med 1996;16:395-406.
4. Unsal H, Zakicier C, Marcais C, Kew MC, Volkman M, Zentgraf H, Isselbacher K, et al. Genetic heterogeneity of hepatocellular carcinoma. Proc Natl Acad Sci U S A 1994;91:822-826.
5. Paterlini P. Poussin K, Kew MC, Franco D, Brechot C. Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma. HEPATOLOGY 1993;21:313-321.
6. Harris CG, Hollstein M. Clinical implications of the p53 tumor suppressor gene. New Engl J Med 1993;329:1318-1327.
7. Vogelstein B, Kinzier KW. p53 function and dysfunction. Cell 1992;70:523-526.
8. Harris CC. Chemical and physical carcinogenesis: Advances and perspectives for the 1990s. Cancer Res 1991;51(Suppl):5023s-5044s.
9. Feitelson MA, Zhu M, Duan L-X, London WT. Hepatitis B X antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene 1993;8:1109-1117.
10. Wang XW, Forrester K, Yeh H, Feitelsohn MA, Gu J-R, Harris CC. Hepatitis B virus x protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci U S A 1994;91:2230-2234.
11. Truant R, Antunovic J, Greenblatt J, Prives C, Cromlish JA. Direct interaction of the hepatitis B virus HBx protein leads to inhibition by HBX of p53 response element-directed transcription. J Virol 1995;69:1851-1859.
12. Ueda H, Ullrich SJ, Gangemi JD, Kappel CA, Ngol L, Feitelsohn MA, Jay G. Functional inactivation but not structural mutation of p53 causes liver cancer. Nat Genet 1995;9:41-47.
13. Henkler F, Waseem N, Golding WHC, Alison MR, Koshy R. Mutant p53 but not hepatitis B virus X protein is present in hepatitis B virus-related human hepatocellular carcinoma. Cancer Res 1995;55:6084-6091.
14. Wang XW, Yeh H, Schaeffer L, Roy R, Moncollin V, Egly J-M, Wang X, et al. p53 modulation of TF11H-associated nucleotide excision repair activity. Nat Genet 1995;10:188-195.
15. McCarthy SA, Symonds HS, Van Dyke T. Regulation of apoptosis in transgenic mice by simian virus 40 T antigen-mediated inactivation of p53. Proc Natl Acad Sci U S A 1994;91:3979-3983.
16. Debbas M, White E. Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev 1993;7:546-554.